Last $27.31 USD
Change Today +0.11 / 0.40%
Volume 608.1K
KITE On Other Exchanges
As of 8:10 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/24/14 - $32.65
52 Week Low
07/16/14 - $21.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KITE PHARMA INC (KITE)

Related News

No related news articles were found.

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc. operates a clinical-stage biopharmaceutical company which focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate includes KTE-C19, a chimeric antigen receptors-based engineered autologous cell therapy for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. The company has collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

27 Employees
Last Reported Date: 08/14/14
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $16.7K
Vice President of Translation Medicine
Total Annual Compensation: $325.0K
Total Annual Compensation: $210.9K
Compensation as of Fiscal Year 2013.

kite pharma inc (KITE) Key Developments

Kite Pharma, Inc. Announces the Publication of Clinical Results in Cohort of Patients Demonstrating the Potential to Treat Aggressive Non-Hodgkin's Lymphoma with an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

Kite Pharma, Inc. announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months. These findings are being published in an article titled, "Chemotherapy-refractory Diffuse Large B-cell Lymphoma and Indolent B-cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor," DOI: 10.1200/JCO.2014.56.2025, which is appearing in the August 25, 2014 issue of the American Society of Clinical Oncology's Journal of Clinical Oncology. The reported Phase 1-2a clinical trial is being conducted at the NCI with Dr. Rosenberg serving as principal investigator. Additional authors of the published study include James N. Kochenderfer, M.D., who presented earlier data for the NCI from the trial at the 55th American Society of Hematology (ASH) Annual Meeting in December 2013. The published clinical trial results relate to patients in the second cohort in the NCI's Phase 1-2a clinical trial of anti-CD19 CAR T cell therapy. The second cohort consists of 15 patients, including two retreated patients from a prior cohort, with advanced B cell malignancies, of which 13 were evaluable for responses, including seven with chemotherapy-refractory DLBCL. Patients received a conditioning regimen of chemotherapy (cyclophosphamide and fludarabine) followed one day later by a single infusion of anti-CD19-CAR T cells. The CAR-expressing T cells were produced from each patient's own peripheral blood mononuclear cells (PBMCs), modified using a gammaretroviral vector encoding the CAR, as well as a CD28 costimulatory moiety.

Kite Pharma, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Kite Pharma, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the second quarter ended June 30, 2014, the company reported a net loss attributable to common stockholders of approximately $17.9 million, compared to a net loss attributable to common stockholders for the quarter ended June 30, 2013 of $1.7 million. Basic and diluted net loss per share for the second quarter of 2014 was $2.27, compared to a net loss per share of $0.32 for the second quarter of 2013. Operating loss was $11,140,000 against $1,433,000 a year ago. For the six months ended June 30, 2014, the company reported a net loss attributable to common stockholders of approximately $21.6 million compared to $2.8 million. Basic and diluted net loss per share was $3.20 compared to $0.51 a year ago. Operating loss was $14,302,000 against $2,522,000 a year ago.

Kite Pharma, Inc.(NasdaqGS:KITE) added to NASDAQ Composite Index

Kite Pharma, Inc. will be added to the NASDAQ Composite Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $27.31 USD +0.11

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies

Industry Analysis


Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at